BiotechTube

Dupilumab + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate-to-Severe Atopic Dermatitis

Conditions

Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic

Trial Timeline

Mar 21, 2017 → Jun 5, 2018

NCT ID
NCT03054428

About Dupilumab + Placebo

Dupilumab + Placebo is a phase 3 stage product being developed by Sanofi for Moderate-to-Severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03054428. Target conditions include Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin.

What happened to similar drugs?

2 of 8 similar drugs in Moderate-to-Severe Atopic Dermatitis were approved

Approved (2) Terminated (0) Active (6)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅dupilumabSanofiApproved
🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Indacaterol + ControlNovartisPhase 3
🔄PonesimodVanda PharmaceuticalsPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3
🔄Zalviso™ 15 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT07053423ApprovedRecruiting
NCT06687967Phase 3Active
NCT06687980Phase 3Active
NCT06191315Phase 3Recruiting
NCT06101095ApprovedActive
NCT05731128Phase 2Active
NCT05097287ApprovedRecruiting
NCT04988022ApprovedCompleted
NCT04417894Phase 3Completed
NCT04442269Phase 2Completed
NCT04512339Phase 2UNKNOWN
NCT04400318ApprovedCompleted
NCT04033367ApprovedCompleted
NCT03749148Phase 2Completed
NCT03749135Phase 2Completed
NCT03633617Phase 3Completed
NCT03389893ApprovedTerminated
NCT03359356Phase 2Completed
NCT03054428Phase 3Completed
NCT02379052Phase 2Completed

Competing Products

13 competing products in Moderate-to-Severe Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314Jiangsu Hengrui MedicinePhase 1
25
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
36
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
dupilumabSanofiApproved
43
dupilumabSanofiPre-clinical
26
PonesimodVanda PharmaceuticalsPhase 3
37
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
Zalviso™ 15 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30